BTIG Comments Positively on Arcus Biosciences (RCUS): 'we see today’s news as positive'
Tweet Send to a Friend
BTIG analyst Kaveri Pohlman reiterated a Buy rating and $70.00 price target on Arcus Biosciences (NYSE: RCUS).The analyst comments "Cabometyx’s ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
